The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2

Biochemical Pharmacology

Volumn 88, Issue 2, 2014, Pages 245-252

  Gu, Rui ^a   Hibbs, David E ^a   Ong, Jennifer A ^a   Edwards, Robert J ^b   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Axitinib; CYP1A2 inhibitor; Cytochrome P450; Molecular modeling; Multikinase inhibitor

Indexed keywords

AXITINIB; CEDIRANIB; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; ERLOTINIB; ETHOXYRESORUFIN; ETHOXYRESORUFIN DEETHYLASE; GEFITINIB; IMATINIB; LINIFANIB; MOTESANIB; MUBRITINIB; NERATINIB; NILOTINIB; O DEMETHYLASE; PAZOPANIB; PELITINIB; PYRIDINE; TOLBUTAMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DEBENZYLATION; DRUG BINDING; DRUG POTENCY; DRUG TRANSFORMATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME METABOLISM; MALE; MIDDLE AGED; MOLECULAR MODEL; OXIDATION; PRIORITY JOURNAL; YOUNG ADULT;

7-ETHOXYRESORUFIN (PUBCHEM CID: 3294); AXITINIB; AXITINIB (PUBCHEM CID: 6450551); CEDIRANIB (PUBCHEM CID: 9933475); CYP1A2 INHIBITOR; CYTOCHROME P450; IMATINIB (PUBCHEM CID: 5291); LINIFANIB (PUBCHEM CID: 11485656); MOLECULAR MODELING; MOTESANIB (PUBCHEM CID: 11667893); MULTIKINASE INHIBITOR; NERATINIB (PUBCHEM CID: 9915743); NILOTINIB (PUBCHEM CID: 644241);

ADULT; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MICROSOMES, LIVER; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; YOUNG ADULT;

EID: 84895558344     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.016     Document Type: Article

References (44)

1. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, and S. Fanning et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 5 1996 561 566
2. Y. Chen, M.A. Tortorici, M. Garrett, B. Hee, K.J. Klamerus, and Y.K. Pithavala Clinical pharmacology of axitinib Clin Pharmacokinet 52 9 2013 713 725
3. A. Haouala, N. Widmer, M.A. Duchosal, M. Montemurro, T. Buclin, and L.A. Decosterd Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib Blood 117 8 2011 e75 e87
4. J.R. Infante, S.F. Jones, J.C. Bendell, F.A. Greco, D.A. Yardley, and C.M. Lane et al. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine Cancer Chemother Pharmacol 69 1 2012 137 144
5. A. Awada, A. Hendlisz, O. Christensen, C.D. Lathia, S. Bartholomeus, and F. Lebrun et al. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours Eur J Cancer 48 4 2012 465 474
6. M.F. Kozloff, L.P. Martin, M. Krzakowski, T.A. Samuel, T.A. Rado, and E. Arriola et al. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours Br J Cancer 107 8 2012 1277 1285
7. R.J. Edwards, D.A. Adams, P.S. Watts, D.S. Davies, and A.R. Boobis Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans Biochem Pharmacol 56 3 1998 377 387
8. J. Chen, M. Murray, C. Liddle, X.M. Jiang, and G.C. Farrell Down-regulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis Hepatology 22 2 1995 580 587
9. M. Murray, L. Zaluzny, and G.C. Farrell Impaired androgen 16α-hydroxylation in hepatic microsomes from carbon tetrachloride- cirrhotic male rats Gastroenterology 93 1 1987 141 147
10. R.A. Prough, M.D. Burke, and R.T. Mayer Direct fluorometric methods for measuring mixed function oxidase activity Methods Enzymol 52 1978 372 377
11. D.J. Back, J.F. Tjia, J. Karbwang, and J. Colbert In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines Br J Clin Pharmacol 26 1 1988 23 29
12. R.G. Knodell, S.D. Hall, G.R. Wilkinson, and F.P. Guengerich Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition J Pharmacol Exp Ther 241 3 1987 1112 1119
13. E. Vielnascher, M. Spatzenegger, A. Mayrhofer, P. Klinger, and W. Jager Metabolism of dextromethorphan in human liver microsomes: a rapid HPLC assay to monitor cytochrome P450 2D6 activity Die Pharmazie 51 8 1996 586 588
14. M.T. Donato, N. Jimenez, J.V. Castell, and M.J. Gomez-Lechon Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes Drug Metab Dispos 32 7 2004 699 706
15. F. d'Esposito, N. Nebot, R.J. Edwards, and M. Murray Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease Brit J Clin Pharmacol 70 3 2010 400 408
16. I.H. Segel Enzyme kinetics: behaviour and analysis of rapid equilibrium and steady-state enzyme systems 1975 Wiley-Interscience New York
17. M. Murray In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver Biochem Pharmacol 42 11 1991 2107 2114
18. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, and T.A. Halgren et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J Med Chem 49 21 2006 6177 6196
19. S. Sansen, J.K. Yano, R.L. Reynald, G.A. Schoch, K.J. Griffin, and C.D. Stout et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2 J Biol Chem 282 19 2007 14348 14355
20. P. Vasanthanathan, L. Olsen, F.S. Jørgensen, N.P. Vermeulen, and C. Oostenbrink Computational prediction of binding affinity for CYP1A2-ligand complexes using empirical free energy calculations Drug Metab Dispos 38 8 2010 1347 1354
21. S. Sivapathasundaram, P. Magnisali, N.G. Coldham, L.C. Howells, M.J. Sauer, and C. Ioannides A study of the expression of the xenobiotic-metabolising cytochrome P450 proteins and of testosterone metabolism in bovine liver Biochem Pharmacol 62 5 2001 635 645
22. C.B. Marcus, M. Murray, and C.F. Wilkinson Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450 Xenobiotica 15 4 1985 351 362
23. M. Murray, and S.L. Field Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants Biochem Pharmacol 43 10 1992 2065 2071
24. M.R. Franklin, and L.B. Hathaway 2-Diethylaminoethyl-2,2- diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol Drug Metab Dispos 36 12 2008 2539 2546
25. R.P. Ortiz de Montellano Cytochrome P-450: structure, mechanism and biochemistry 1986 Plenum New York 217 271
26. F.P. Guengerich Cytochrome P-450: structure, mechanism, and biochemistry 2nd ed. 1995 Plenum New York 473 535
27. M. Murray Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes Int J Mol Med 3 3 1999 227 238
28. D.F. Lewis, B.G. Lake, M. Dickins, Y.F. Ueng, and P.S. Goldfarb Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure Xenobiotica 33 3 2003 239 254
29. N.E. Hadjokas, R. Dai, F.K. Friedman, M.J. Spence, B.J. Cusack, and R.E. Vestal et al. Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells Br J Pharmacol 136 3 2002 347 352
30. A. Parikh, P.D. Josephy, and F.P. Guengerich Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties Biochemistry 38 17 1999 5283 5289
31. B.B. Palma, E. Silva, M. Sousa, C.R. Vosmeer, J. Lastdrager, and J. Rueff et al. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression Pharmacogenomics J 10 6 2010 478 488
32. E. Roeland, K.A. Shimabukuro, P.T. Fanta, B.H. Parker, M. Hwang, and T.R. Reid Early outcome of a phase I study of interrupted pulse dosed axitinib combined with FOLFOX or FOLFIRI in refractory metastatic colorectal cancer J Clin Oncol 30 Suppl. 4 2012 A473
33. E.E. Cohen, L.S. Rosen, E.E. Vokes, M.S. Kies, A.A. Forastiere, and F.P. Worden et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 29 2008 4708 4713
34. O. Rixe, R.M. Bukowski, M.D. Michaelson, G. Wilding, G.R. Hudes, and O. Bolte et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 11 2007 975 984
35. H.S. Rugo, A.T. Stopeck, A.A. Joy, S. Chan, S. Verma, and A. Lluch et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer J Clin Oncol 29 18 2011 2459 2465
36. J.H. Schiller, T. Larson, S.H. Ou, S. Limentani, A. Sandler, and E. Vokes et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 23 2009 3836 3841
37. J.P. Spano, C. Chodkiewicz, J. Maurel, R. Wong, H. Wasan, and C. Barone et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 9630 2008 2101 2108
38. A.M. Filppula, M. Neuvonen, J. Laitila, P.J. Neuvonen, and J.T. Backman Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response Drug Metab Dispos 41 1 2013 50 59
39. N. Nebot, S. Crettol, F. d'Esposito, B. Tattam, D.E. Hibbs, and M. Murray Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes Br J Pharmacol 161 5 2010 1059 1069
40. Y.K. Pithavala, W. Tong, J. Mount, S.V. Rahavendran, M. Garrett, and B. Hee et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers Invest New Drugs 30 1 2012 273 281
41. S.A. Wrighton, E.G. Schuetz, K.E. Thummel, D.D. Shen, K.R. Korzekwa, and P.B. Watkins The human CYP3A subfamily: practical considerations Drug Metab Rev 32 3-4 2000 339 361
42. M.A. Tortorici, M. Toh, S.V. Rahavendran, R.R. Labadie, C.W. Alvey, and T. Marbury et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics Invest New Drugs 29 6 2011 1370 1380
43. G.C. Farrell, and M. Murray Human cytochrome P450 isoforms: their genetic heterogeneity and induction by omeprazole Gastroenterology 99 3 1990 885 889
44. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1 1994 414 423